About 80 per cent of people living with pulmonary fibrosis (PF) are plagued with a chronic cough. Chronic cough for people living with PF is more than just a symptom of a life threatening disease, it impacts their quality of life.
Tune in as Dr. Ciaran Scallan shares how a Canadian Pulmonary Fibrosis (CPFF) research grant helped launch what will soon be the largest prospective study of cough in interstitial lung disease (ILD). This study is intended to help improve the quality of life for people living with ILD who experience a chronic cough.
“So this all started with the grant we were very lucky to receive from the CPFF in 2021 for $20 ,000. Using that funding, we were able to complete our retrospective study and generate a protocol and we were awarded $191 ,000 from the Hamilton Academy of Health Sciences”, says Dr. Ciaran Scallan while providing a research update to the CPFF Board of Directors. The study will begin recruiting participants in March 2024, mainly from Firestone Institute for Respiratory Health in Hamilton, and anticipate publishing the study results in the fall of 2025.
Dr. Ciaran Scallan at the Firestone Institute for Respiratory Health in Hamilton, Ontario, was awarded $20,000 to study the feasibility of using a sputum (phlegm) guided approach to treat chronic cough in PF patients using inhaled corticosteroids and azithromycin (a macrolide antibiotic) during a 12-week period.
Learn more about CPFF research programs: cpff.ca/research-and-healthca...
Learn more about pulmonary fibrosis cpff.ca